Rein Therapeutics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Working Capital Analysis
Valuation Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-2
Book Value Per Share
$1
Free Cash Flow Per Share
$-1
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity
-139.9%
Return on Assets
-115.5%
Return on Invested Capital
-112.2%
Current Ratio
0.70
Quick Ratio
0.70
Asset Turnover
0.00
Working Capital
$-2M
Net Current Asset Value
$-3M
Invested Capital
$17M
OCF / Net Income
0.39
FCF / Net Income
0.39
Accruals Ratio (Sloan)
-126.3%
Net Debt
$-3M
Net Debt / EBITDA
0.06
Interest Coverage
—
Cash Coverage
—
Capex Coverage
—
Tangible Common Equity
$-3M
TCE / Total Assets
-12.1%
Goodwill / Total Assets
26.2%
NOPAT
$-40M
Cash ROIC
-54.3%
Capex / D&A
—
Reinvestment Rate
0.0%
Book Value 5Y CAGR
6.8%
Stock Price (FY-end)
$1
Market Cap
$30M
P/B Ratio
1.74
P/TB Ratio
7.04
Enterprise Value
$26M
FCF Yield
-65.6%
Shareholder Yield
-7.5%
R&D Yield
37.4%
Capex Yield
—
Shares Variation (YoY)
41.8%
Beta (5Y)
1.01
Cost of Equity
9.5%
52W High
$3
52W Low
$1
Trailing Return 1Y
-48.0%
Trailing Return 5Y
-95.0%
F-Score (Piotroski)
1.00
Z-Score (Altman)
-27.82
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.